NASDAQ:MEDP - Medpace Stock Price, Forecast & News

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) posted its quarterly earnings results on Tuesday, October, 29th. The company reported $0.71 earnings per share for the quarter, meeting the Zacks' consensus estimate of $0.71. The firm had revenue of $216.20 million for the quarter, compared to the consensus estimate of $217.14 million. Medpace had a return on equity of 17.06% and a net margin of 11.35%. The company's revenue for the quarter was up 20.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Medpace.

Medpace will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

4 equities research analysts have issued 1 year price objectives for Medpace's shares. Their forecasts range from $62.00 to $87.00. On average, they anticipate Medpace's stock price to reach $75.33 in the next twelve months. This suggests that the stock has a possible downside of 24.7%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Press coverage about MEDP stock has trended extremely negative on Thursday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Medpace earned a media sentiment score of -4.3 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for Medpace.

Some companies that are related to Medpace include EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), Charles River Laboratories Intl. (CRL), PRA Health Sciences (PRAH), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Sorrento Therapeutics (SRNE), Anavex Life Sciences (AVXL), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF) and Luna Innovations (LUNA).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), EXACT Sciences (EXAS), Alibaba Group (BABA), Adobe (ADBE), Baidu (BIDU), Paycom Software (PAYC), Veeva Systems (VEEV), Fortinet (FTNT), Roku (ROKU) and Arista Networks (ANET).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Pendal Group Ltd (3.55%), State Street Corp (2.21%), Renaissance Technologies LLC (1.63%), Acadian Asset Management LLC (1.47%), Geode Capital Management LLC (1.19%) and Goldman Sachs Group Inc. (1.11%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Russell Investments Group Ltd., PNC Financial Services Group Inc., Marshall Wace LLP, Goldman Sachs Group Inc., AQR Capital Management LLC, SG Americas Securities LLC and Bowling Portfolio Management LLC. Company insiders that have sold Medpace company stock in the last year include Jesse J Geiger and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Man Group plc, Renaissance Technologies LLC, California Public Employees Retirement System, Bank of Montreal Can, Great West Life Assurance Co. Can and McGuire Investment Group LLC. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $100.05.

Medpace has a market capitalization of $3.60 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]